[{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"9ce1ae1c-3677-40b4-81f0-ce916a71323c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02633059","created_at":"2025-09-06T20:42:42.259Z","updated_at":"2025-09-06T20:42:42.259Z","phase":"Phase 1/2","brief_title":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02633059","lead_sponsor":"Mayo Clinic","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-09-12"},{"id":"ba5e9c1f-9156-4368-acb2-f775396afb8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04029688","created_at":"2021-01-18T19:46:44.421Z","updated_at":"2024-07-02T16:35:12.360Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","source_id_and_acronym":"NCT04029688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-03-29"},{"id":"a8b6f6a9-6202-45d1-8f50-d1a889349779","acronym":"NOA-20","url":"https://clinicaltrials.gov/study/NCT03158389","created_at":"2021-01-18T15:34:18.016Z","updated_at":"2024-07-02T16:35:35.452Z","phase":"Phase 1/2","brief_title":"NCT Neuro Master Match - N²M² (NOA-20)","source_id_and_acronym":"NCT03158389 - NOA-20","lead_sponsor":"University Hospital Heidelberg","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Ibrance (palbociclib) • Alecensa (alectinib) • temsirolimus • Erivedge (vismodegib) • idasanutlin (RG7388) • Apocept (asunercept)"],"overall_status":"Completed","enrollment":" Enrollment 228","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2023-09-28"},{"id":"21fcb4a3-2428-4756-bda3-81d1398926ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01773408","created_at":"2021-01-18T07:49:00.137Z","updated_at":"2024-07-02T16:37:26.234Z","phase":"Phase 1","brief_title":"A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia","source_id_and_acronym":"NCT01773408","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53 • GDF15","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-01-25"},{"id":"68437971-9714-4d65-858d-5223d19a23aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462175","created_at":"2021-01-18T06:04:54.371Z","updated_at":"2024-07-02T16:37:27.822Z","phase":"Phase 1","brief_title":"A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia","source_id_and_acronym":"NCT01462175","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53 • MDM2 • GDF15 • CDKN1A","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MDM2 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-11-02"}]